Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: March 2013

Chapter 2 - Migraine

References

[1] The International Classification of Headache Disorders, 2nd Edition. Cephalalgia 2004; 24; (suppl 1): 9–160.
[2] BlauJN. Migraine prodromes separated from the aura: complete migraine. BMJ 1980; 281: 658–81.
[3] NosedaR, KainzV, JakubowskiM, GooleyJet al. A neural mechanism for exacerbation of headache by light. Nature Neuroscience 2010; 13: 239–45.
[4] KelmanL. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007; 27: 394–402.
[5] RussellMB, RasmussenBK, FengerK, OlesenJ. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia 1996; 16: 239–45.
[6] FisherCM. Late-life migraine accompaniments-further experience. Stroke 1986; 17: 1033–42.
[7] LeãoA. Spreading depression of activity in the cerebral cortex. J Neurophys 1944; 7: 359–90.
[8] AuroraSK, AhmadBK, WelchKMA, BhardhwajP, RamadanNM. Transcranial magnetic stimulation confirms hyper excitability of occipital cortex in migraine. Neurology 1998; 50: 1111–14.
[9] BowyerSM, AuroraSK, MoranJE, TepleyN, WelchKMA. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann Neurol 2001; 50: 582–7.
[10] DenuelleM, Boulloche, PayouxP, et al. A PET study of photophobia during spontaneous migraine attacks. Neurology 2011; 76: 213–18.
[11] GrahamJR, WolffHG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1939; 39: 737–63.
[12] BolayH, ReuterU, DunnAK, HuangZ, BoasDA, MoskowitzMA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8: 136–42.
[13] MoskowitzMA. Basic mechanisms in vascular headache. Neurol Clin 1990; 8: 801–15.
[14] BrennanKC, Beltran-ParrazalL, Lopez-ValdesHE, TheriotJ, TogaAW, CharlesAC. Distinct vascular conduction with cortical spreading depression. J Neurophysiol 2007; 97: 4143–51.
[15] KimballRW, FriedmanAP, VallejoE. Effect of serotonin in migraine patients. Neurology 1960; 10: 107–11.
[16] WoodsRP, IacoboniM, MazziottaJC. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994; 331: 1689–92.
[17] BahraA, MatharuMS, BuchelC, FrackowiakPSJ, GoadsbyPJ. Brainstem activation specific to migraine headache. The Lancet 2001; 357: 1016–17.
[18] CharlesA. Intercellular calcium waves in glia. Glia 1998; 24: 39–49.
[19] HaydonPG, CarmignotoG. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev 2006; 86: 1009–31.
[20] LauritzenM, OlesenJ. Regional cerebral blood flow during migraine attacks by xenon-133 inhalation and emission tomography. Brain 1984; 107: 447–61.
[21] WelchKMA, NageshV, AuroraSK, GelmanN. Periaqueductal gray matter dysfunction in migraine: cause of burden of illness?Headache 2001; 41: 629–37.
[22] HersheyAD, PowersSW, NelsonTDet al. American Headache Society Pediatric Adolescent Section. Obesity in the pediatric headache population. Headache 2009; 49: 170–7.
[23] BigalME, LiptonRB, HollandPR, GoadsbyPJ, Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007; 68: 1851–61.
[24] HorevA, WirguinI, LantsbergL, IferganeG. A high incidence of migraine with aura among morbidly obese women. Headache 2005; 45: 936–8.
[25] BondDS, VithiananthanS, NashJM, ThomasJG, WingRR. Improvement of migraine headaches in severely obese patients after bariatric surgery. Neurology 2011; 76: 1135–8.
[26] KallweitU, HidalgoH, UhlV, SándorPS. Continuous positive airway pressure therapy is effective for migraines in sleep apnea syndrome. Neurology 2011; 76: 1189–91.
[27] KristiansenHA, KvænrnerKJ, AkreH, ØverlandV, RussellMB. Migraine and sleep apnea in the general population. J Headache Pain 2011; 12: 55–61.
[29] NestoriucY, MartinA. Efficacy of biofeedback for migraine: A meta analysis. Pain 2007; 128: 111–27.
[30] FerrariMD, RoonKI, LiptonRB, GoadsbyPJ. Oral triptans (serotonin 5-HT (1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668–75.
[31] AuroraS, KoriS, BarrodaleP, NelsenA, McDonaldS. Gastric stasis occurs in spontaneous, visually induced and interictal migraine. Headache 2007; 47: 1443–6.
[32] DowsonAJ, MathewNT, PascualJ. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int J Clin Pract 2006; 60: 698–706.
[33] SilbersteinSD, SchulmanEA, McFaddenM. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990; 30: 334–9.
[34] RamadanMN, SilbersteinSD, FreitagFG, GilbertTT, FrishbergGM. Pharmacological management for prevention of migraine. Available at http://www.aan.com/public/practiceguidelines.
[35] AyataC, JinH, KudoC, DalkaraT, MoskowitzM. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006; 59: 652–61.
[36] SchraderH, StovnerLJ, HeldeC, SandT, BovimG. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322: 19.
[37] TronvikE, StovnerLJ, HeldeG, SandT, BovimG. Prophylactic treatment of migraine with an angiotensin II receptor blocker. JAMA 2003; 289: 65–9.
[38] CampistolJ, CamposJ, CasasC, HerranzJL. Topiramate in the prophylactic treatment of migraine in children. J Child Neurol 2005; 20: 251–3.
[39] PascualJ, RivasMT, LeiraR. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand 2007; 115: 181–3.
[40] DrakeME, GreathouseNI, RennerJB, ArmentbrightAD. Open-label zonisamide for refractory migraine. Clin Neuropharmacol 2004; 27: 278–80.
[41] MathewNT, RapoportA, SaperJ, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119–28.
[42] KruszJC, BelangerJ, MillsC. Tizanidine: a novel effective agent for the treatment of chronic headaches. Headache 2000; 11: 41–5.
[43] SilbersteinSD, PeresM, HopkinsMM, SchechterAL, YoungWB, RozenTD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache 2002; 42: 515–18.
[44] LucianiR, CarterD, MannixL, HempfillM, DiamondM, CadyR. Prevention of migraine during prodrome with naratriptan. Cephalalgia 2000; 20: 122–6.
[45] MauskopA, AlturaBT, CraccoRQ, AlteraBM. Intravenous magnesium sulfate relieves acute migraine in patients with low serum ionized magnesium levels. Clin Sci 1995; 89: 633–6.
[46] SchoenenJ, JacquyJ, LanaertsM. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology 1998; 50: 466–70.
[47] SándorPS, Di ClementeL, CoppolaG. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005; 64: 713–15.
[48] PfaffenrathV, DienerHC, FischerM, FriedeM, Henneicke-von ZepelinHH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis – a double-blind, multicentre randomized placebo-controlled dose-response study. Cephalalgia 2002; 22: 523–32.
[49] LiptonB, GobelH, WilksK, MauskopA. Efficacy of petasites (an extract from petasites rhizone) 50 and 75 mg for prophylaxis of migraine: results of a randomized, double-blind, placebo controlled study. (abstract). Neurology 2002; 58: A472.
[50] LindeK, AllaisG, BrinkhausB, ManheimerE, VickersA, WhiteAR. Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev 2009 (1):CD001218.
[51] DurhamPL, CadyR. Insights into the mechanism of onabotulinumtoxin A in chronic migraine. Headache 2011; 51: 1573–7.
[52] JakubowskiM, McAllisterP, BajwaZH, et al. Exploding vs imploding headache in migraine prophylaxis with Botulinum Toxin A. Pain 2006; 125: 286–95.
[53] KowacsPA, PiovesanEJ, TepperSJ. Rejection and acceptance of possible side effects of migraine prophylactic drugs. Headache 2009; 49: 1022–7.
[54] FDA Alert. Combined use of 5-hydroxytriptamine receptor agonists (triptans), selective serotonin reuptake inhibitors SSRIs), or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome. July 2006.
[55] EvansRW, TepperSJ, ShapiroRE, Sun-EdelsteinC, TietjenGE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache 2010; 50: 1089–99.